Office of The Director, National Institutes of Health; Notice of Meeting, 12399 [2018-05740]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 55 / Wednesday, March 21, 2018 / Notices
Guidances/default.htm, https://
www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatory
Information/Guidances/default.htm, or
https://www.regulations.gov.
Dated: March 15, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–05659 Filed 3–20–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Office of The Director, National
Institutes of Health; Notice of Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Advisory Committee to
the Director, National Institutes of
Health.
The meeting will be held as a
teleconference call only and is open to
the public to dial-in for participation.
Individuals who plan to dial-in to the
meeting and need special assistance or
other reasonable accommodations in
order to do so, should notify the Contact
Person listed below in advance of the
meeting.
Name of Committee: Advisory Committee
to the Director, National Institutes of Health.
Date: April 6, 2018.
Time: 4:00 p.m. to 5:30 p.m.
Agenda: Report from the Working Group
on Ethical Consideration for Industry
Partnership on Research to Help End the
Opioid Crisis.
Place: National Institutes of Health,
Building 1, One Center Drive, Bethesda, MD
20892 (Telephone Conference Call), 888–
324–9616, Access Code: 1986191.
Contact Person: Gretchen Wood, Staff
Assistant, National Institutes of Health,
Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892,
301–496–4272, Woodgs@od.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
acd.od.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
18:34 Mar 20, 2018
Dated: March 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–05740 Filed 3–20–18; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Jkt 244001
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Approaches to Identify and Care for
Individuals with Inherited Cancer
Syndromes.
Date: April 26, 2018.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Room
7W640 Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Bethesda, MD
20892–9750, 240–276–5179, saejeong.kim@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–3: NCI
Clinical and Translational Exploratory/
Developmental Studies.
Date: June 5–6, 2018.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Ombretta Salvucci, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
12399
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Bethesda, MD
20892–9750, 240–276–7286, salvucco@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: March 16, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–05737 Filed 3–20–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the National Center for
Advancing Translational Sciences.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cures Acceleration
Network Review Board.
Date: May 10, 2018.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD
E:\FR\FM\21MRN1.SGM
21MRN1
]]>Agencies
[Federal Register Volume 83, Number 55 (Wednesday, March 21, 2018)]
[Notices]
[Page 12399]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-05740]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of The Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Advisory Committee
to the Director, National Institutes of Health.
The meeting will be held as a teleconference call only and is open
to the public to dial-in for participation. Individuals who plan to
dial-in to the meeting and need special assistance or other reasonable
accommodations in order to do so, should notify the Contact Person
listed below in advance of the meeting.
Name of Committee: Advisory Committee to the Director, National
Institutes of Health.
Date: April 6, 2018.
Time: 4:00 p.m. to 5:30 p.m.
Agenda: Report from the Working Group on Ethical Consideration
for Industry Partnership on Research to Help End the Opioid Crisis.
Place: National Institutes of Health, Building 1, One Center
Drive, Bethesda, MD 20892 (Telephone Conference Call), 888-324-9616,
Access Code: 1986191.
Contact Person: Gretchen Wood, Staff Assistant, National
Institutes of Health, Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892, 301-496-4272,
[email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://acd.od.nih.gov, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: March 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-05740 Filed 3-20-18; 8:45 am]
BILLING CODE 4140-01-P
